S-0139 (Shionogi).
Shionogi and GlaxoSmithKline (GSK), as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals LLC, are developing S-0139 (SB-737004), an endothelin-A (ETA) antagonist, for the potential treatment of hemorrhagic and ischemic stroke [223386], [252007], [426822], [426830]. By 1999, the compound was in phase II trials in Japan for stroke [348554]; phase II trials were ongoing in March 2002 [446957]. As of May 2000, Shionogi was preparing to develop the drug in the US and Europe [370602]. As of May 2001, a phase I European trial was in preparation [410912]; which was underway by November 2001 [429990]. In July 2001, Shionogi and GSK signed a letter of intent to create a joint venture that was initially to have exclusive rights to develop and commercialize four compounds contributed by Shionogi and one by GSK, including S-0139 14167621. The agreement wasfinalized in October 2001 [426569], [426822]. In August 1999, Lehman Brothers gave S-0139 a 10% probability of reaching the market with an expected launch in 2005. Sales were expected to peak at US $50 million in 2012 [349228].
Abbott Laboratories, Santa Clara, CA 95054, USA. ruth.r.wuwong@abbott.com
J Ruth
JR
Wu-Wong
D000818:Animals; D002109:Caffeic Acids / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000639:trends; D065128:Endothelin Receptor Antagonists; D006801:Humans; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D044022:Receptor, Endothelin A; D020521:Stroke / Q000188:drug therapy
D002109:Caffeic Acids; D065128:Endothelin Receptor Antagonists; D044022:Receptor, Endothelin A; C086421:S 0139; D009828:Oleanolic Acid